1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nicox SA.
  6. News
  7. Summary
    COX   FR0013018124

NICOX SA.

(COX)
  Report
Real-time Euronext Paris  -  11:35 2022-07-04 am EDT
1.718 EUR   -0.12%
06/22Nicox Extraordinary General Meeting of July 11, 2022
GL
06/22Nicox Extraordinary General Meeting of July 11, 2022
AQ
06/15NICOX : Suggested agenda and summary of the resolutions submitted to the approval of the Extraordinary shareholder meeting (translation for information purposes)
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Ophthalmology Group Nicox Appoints New CEO, Chairman

05/16/2022 | 02:01am EDT


© MT Newswires 2022
All news about NICOX SA.
06/22Nicox Extraordinary General Meeting of July 11, 2022
GL
06/22Nicox Extraordinary General Meeting of July 11, 2022
AQ
06/15NICOX : Suggested agenda and summary of the resolutions submitted to the approval of the E..
PU
06/15NICOX : How to participate in the Extraordinary shareholder meeting
PU
06/14NICOX : 2022 Ordinary Shareholder Meeting
GL
06/14NICOX : 2022 Ordinary Shareholder Meeting
GL
06/03NICOX : 2022 Extraordinary Shareholder Meeting
GL
06/03NICOX : 2022 Extraordinary Shareholder Meeting
AQ
06/03Ophthalmology Group Nicox To Release Data From Late-stage Glaucoma Drug Trial In Novemb..
MT
06/03Nicox Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to Nov..
GL
More news
Financials
Sales 2022 9,03 M 9,41 M 9,41 M
Net income 2022 -20,3 M -21,2 M -21,2 M
Net cash 2022 2,49 M 2,59 M 2,59 M
P/E ratio 2022 -3,66x
Yield 2022 -
Capitalization 74,3 M 77,4 M 77,4 M
EV / Sales 2022 7,95x
EV / Sales 2023 6,44x
Nbr of Employees 33
Free-Float 89,1%
Chart NICOX SA.
Duration : Period :
Nicox SA. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NICOX SA.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 1,72 €
Average target price 11,50 €
Spread / Average Target 569%
EPS Revisions
Managers and Directors
Andreas Rutger Segerros Chief Executive Officer
Sandrine Gestin Vice President-Finance
Michele Garufi Chairman
Doug Hubatsch Chief Scientific Officer
Jean-François Labbé Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NICOX SA.-32.68%77
MERCK KGAA-27.00%74 935
KYOWA KIRIN CO. LTD.-3.19%12 062
SK BIOPHARMACEUTICALS CO., LTD.-25.62%4 240
BETTA PHARMACEUTICALS CO., LTD.-26.86%3 452
YUHAN CORPORATION-8.21%2 930